Lot 1
Original notice title
Italy – Pharmaceutical products – Bando SDA_Farmaci e Vaccini 2025
Opportunity Score
Why this score?
Opportunity
75 / 100
Complexity
60 / 100
Risk factors
Procurement documents have not been analyzed; key requirements, eligibility criteria, and contract terms are unknown.
Structured data indicates EU funding, but XML notice states no EU funds. This could affect compliance requirements.
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- EUR 8000M estimated value
- Dynamic Purchasing System (DPS)
- Supplies contract
- 1 lot
- Duration 1825 DAY
- Supply of pharmaceutical products (CPV 33600000) including drugs, vaccines, blood derivatives, and contrast media.
- Delivery to health authorities in Abruzzo (NUTS ITF11) and other aggregating entities.
Show full summary
This is a restricted procedure for a Dynamic Purchasing System (DPS) for the supply of pharmaceuticals, including drugs, blood derivatives, vaccines, and contrast media, to health authorities in the Abruzzo region and other aggregating entities. The DPS is managed by AreaCom, the regional procurement agency. The estimated total value is EUR 8,000,000,000, with a duration of 5 years (1825 days). The award is based solely on price. Only one lot is defined. Submission deadline is 2030-09-04. The structured data indicates EU funding, but the XML notice states no EU funds, creating an inconsistency.
Risks
Procurement documents have not been analyzed; key requirements, eligibility criteria, and contract terms are unknown.
Structured data indicates EU funding, but XML notice states no EU funds. This could affect compliance requirements.
Restricted procedure — pre-qualification required
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Tenderers must be able to supply the full range of pharmaceutical products as per the contract specification.
- Compliance with Italian procurement law (D.Lgs. 36/2023) and EU Directive 2014/24/EU.
Administrative
- Participation in a restricted procedure: interested parties must submit a request to participate and be selected.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
L'Aquila, ITA
Buyer profile
Identifier
91022630676
Activity
General public services
Lots (1)
LOT-0001
Lot 1
Supply of pharmaceuticals, vaccines, blood derivatives, and contrast media for health authorities in Abruzzo.
EUR 8B
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
Prezzo
Value note
Show original TED data
Original lot title
Lotto 1
Original TED description
Lotto 1
Procurement Details
- Publication date
- 03 Sep 2025
- Languages
- Italian
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 576499-2025
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
75 / 100
Complexity
60 / 100
Risk factors
Procurement documents have not been analyzed; key requirements, eligibility criteria, and contract terms are unknown.
Structured data indicates EU funding, but XML notice states no EU funds. This could affect compliance requirements.
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications